{"result": {"id": "6bd2e427-7e8a-4b3b-9910-16a75195f9ae", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME<|>EVENT<|>A type of acute coronary syndrome characterized by ST-segment elevation on ECG\")  \n##  \n(\"entity\"<|>NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME<|>EVENT<|>A type of acute coronary syndrome without ST-segment elevation on ECG\")  \n##  \n(\"entity\"<|>ACUTE MYOCARDIAL INFARCTION<|>EVENT<|>A heart attack caused by blockage of coronary arteries\")  \n##  \n(\"entity\"<|>CORONARY ARTERY DISEASE<|>EVENT<|>A condition involving narrowed or blocked coronary arteries\")  \n##  \n(\"entity\"<|>ANGINA<|>EVENT<|>Chest pain caused by reduced blood flow to the heart\")  \n##  \n(\"entity\"<|>HYPERTENSION<|>EVENT<|>High blood pressure, a major risk factor for cardiovascular diseases\")  \n##  \n(\"entity\"<|>HEART FAILURE<|>EVENT<|>A chronic condition where the heart cannot pump blood effectively\")  \n##  \n(\"entity\"<|>CORONARY ARTERY BYPASS GRAFTING<|>EVENT<|>A surgical procedure to improve blood flow to the heart\")  \n##  \n(\"entity\"<|>SACUBITRIL/VALSARTAN<|>ORGANIZATION<|>A combination drug (ARNI) used for heart failure and hypertension\")  \n##  \n(\"entity\"<|>LOOP DIURETIC<|>ORGANIZATION<|>A class of diuretics often used in heart failure management\")  \n##  \n(\"relationship\"<|>ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME<|>ACUTE MYOCARDIAL INFARCTION<|>STEMI is a type of acute myocardial infarction<|>9\")  \n##  \n(\"relationship\"<|>NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME<|>ACUTE MYOCARDIAL INFARCTION<|>NSTEMI is a type of acute coronary syndrome<|>8\")  \n##  \n(\"relationship\"<|>CORONARY ARTERY DISEASE<|>ANGINA<|>Coronary artery disease can cause angina symptoms<|>8\")  \n##  \n(\"relationship\"<|>HYPERTENSION<|>HEART FAILURE<|>Hypertension is a major cause of heart failure<|>9\")  \n##  \n(\"relationship\"<|>HYPERTENSION<|>CORONARY ARTERY DISEASE<|>Hypertension is a risk factor for coronary artery disease<|>8\")  \n##  \n(\"relationship\"<|>SACUBITRIL/VALSARTAN<|>ARNI<|>Sacubitril/valsartan is an ARNI class medication<|>10\")  \n##  \n(\"relationship\"<|>LOOP DIURETIC<|>DIURETIC<|>Loop diuretics are a subclass of diuretics<|>9\")  \n##  \n(\"relationship\"<|>Β RECEPTOR BLOCKER<|>ACUTE MYOCARDIAL INFARCTION<|>Beta-blockers are used post-myocardial infarction<|>8\")  \n##  \n(\"relationship\"<|>RAS INHIBITOR<|>HEART FAILURE<|>RAS inhibitors are first-line for heart failure<|>9\")  \n##  \n(\"relationship\"<|>CCB<|>ANGINA<|>Calcium channel blockers can reduce angina episodes<|>8\")  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558755, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 829, "prompt_tokens": 3275, "total_tokens": 4104, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3200}, "prompt_cache_hit_tokens": 3200, "prompt_cache_miss_tokens": 75}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 合并稳 定性冠心病患者 ,CCB、RAS抑制剂、β受体阻滞剂均 有充分的证据可以应用 ,其中 , CCB还可以降低心肌 氧耗量 ,减少心绞痛发作[244,557-558] 。使用上述药物血 压控制不理想 ,可以联合使用利尿剂。\n\n\n\n　　　(2)非 ST段抬高急性冠脉综合征 : 以 CCB、β受 体阻滞剂 作 为 首 选 , 血 压 控 制 不 理 想 , 可 联 合 使 用 RAS抑制剂以及利尿剂 。另外 , 当考虑存在血管痉挛 因素时 ,应该注意避免使用大剂量的 β受体阻滞剂 , 因 其有可能诱发冠状动脉痉挛[559] 。\n　　　(3)ST段抬高的急性心肌梗死 :高血压合并心肌 梗死患者,β受体阻滞剂和 RAS抑制剂在心肌梗死后 长期服用可以显著改善远期预后 ,没有禁忌证者应早 期使用[244,557-558] 。血压控制不理想时可以联合使用 CCB及利尿剂 。沙库巴曲缬沙坦降压的适应证在世 界范围内首先于我国获批使用 ,基于其在心力衰竭患 者中使用的证据[560]  , 以及最新在急性心肌梗死患者 中应用的研究证据[561-562]  ,如果患者合并 LVH 和射血 分数降低 ,在 RAS抑制剂应用的基础上 ,考虑沙库巴 曲缬沙坦在降低冠心病死亡、非致死性心肌梗死、心绞 痛住院或冠状动脉血运重建术的复合终点方面可能获 益 ,不过应监测低血压的不良反应。\n8.4   高血压合并心力衰竭\n\n要点 8D   高血压合并心力衰竭\n　　　·对于高血压合并心力衰竭患者 ,推荐的降压治 疗目标为<130/80mmHg( Ⅰ ,C) 。\n　　　· 高血压合并 HFrEF患者 , 降压治疗首先推荐 ARNI或 ACEI(不能耐受者可以使用 ARB) 、β受体\n阻滞剂、MRA、SGLT2i( Ⅰ ,A) ,及袢利尿剂( Ⅰ ,B) 。 ·高血压合并 HFpEF患者 ,降压治疗首先推荐\n　SGLT2i( Ⅰ ,A) 、利尿剂 ( Ⅰ , C) 、ARNI( Ⅱ a, B) 或 ARB( Ⅱb,B) 、MRA( Ⅱa,B) 。\n\n　8.4.1  流行病学特点    高血压是心力衰竭的主要致 病病因 。研究显示 ,我国住院心力衰竭患者中 56.3% 合并有高血压 ;其中 , HFrEF和 HFpEF患者合并高 血压的比例分别为49.4%和64.5%[563] 。最新注册登 记研究的结果相似 , HFpEF患者中 65.2%合并有高 血压[564] 。在亚洲地区 , 心力衰竭患者合并高血压比 例为 52%~71%[565] 。\n　8.4.2   降压治疗临床获益    积极降压治疗可以预�\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>CCB<|>ORGANIZATION<|>Calcium Channel Blockers are used to treat stable coronary artery disease and reduce myocardial oxygen consumption and angina attacks\")  \n##  \n(\"entity\"<|>RAS INHIBITOR<|>ORGANIZATION<|>Renin-Angiotensin System inhibitors are used in hypertension and heart failure management\")  \n##  \n(\"entity\"<|>Β RECEPTOR BLOCKER<|>ORGANIZATION<|>Beta-blockers are used to manage hypertension, coronary syndromes, and heart failure\")  \n##  \n(\"entity\"<|>DIURETIC<|>ORGANIZATION<|>Diuretics are used for blood pressure control and fluid management in heart failure\")  \n##  \n(\"entity\"<|>ARNI<|>ORGANIZATION<|>Angiotensin Receptor-Neprilysin Inhibitor is recommended for heart failure with reduced ejection fraction\")  \n##  \n(\"entity\"<|>ACEI<|>ORGANIZATION<|>Angiotensin-Converting Enzyme Inhibitors are used in heart failure management\")  \n##  \n(\"entity\"<|>ARB<|>ORGANIZATION<|>Angiotensin Receptor Blockers are alternatives to ACE inhibitors in heart failure\")  \n##  \n(\"entity\"<|>MRA<|>ORGANIZATION<|>Mineralocorticoid Receptor Antagonists are used in heart failure management\")  \n##  \n(\"entity\"<|>SGLT2I<|>ORGANIZATION<|>Sodium-Glucose Cotransporter-2 Inhibitors are recommended for heart failure\")  \n##  \n(\"entity\"<|>HFREF<|>EVENT<|>Heart Failure with Reduced Ejection Fraction is a condition where the heart's pumping efficiency is diminished\")  \n##  \n(\"entity\"<|>HFPEF<|>EVENT<|>Heart Failure with Preserved Ejection Fraction is a condition where the heart's relaxation is impaired\")  \n##  \n(\"relationship\"<|>CCB<|>RAS INHIBITOR<|>CCB and RAS inhibitors are both used in hypertension and coronary artery disease management<|>6\")  \n##  \n(\"relationship\"<|>Β RECEPTOR BLOCKER<|>RAS INHIBITOR<|>Beta-blockers and RAS inhibitors are both used in heart failure and post-myocardial infarction care<|>7\")  \n##  \n(\"relationship\"<|>DIURETIC<|>RAS INHIBITOR<|>Diuretics and RAS inhibitors are combined for blood pressure control<|>5\")  \n##  \n(\"relationship\"<|>ARNI<|>ACEI<|>ARNI is an alternative to ACEI in heart failure with reduced ejection fraction<|>8\")  \n##  \n(\"relationship\"<|>ARNI<|>ARB<|>ARNI is used when ARB or ACEI are not tolerated in heart failure<|>7\")  \n##  \n(\"relationship\"<|>SGLT2I<|>HFPEF<|>SGLT2 inhibitors are recommended for heart failure with preserved ejection fraction<|>8\")  \n##  \n(\"relationship\"<|>MRA<|>HFREF<|>Mineralocorticoid Receptor Antagonists are used in heart failure with reduced ejection fraction<|>7\")  \n##  \n(\"relationship\"<|>HFREF<|>HFPEF<|>Both are types of heart failure with different pathophysiological mechanisms<|>4\")  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_a02fcc33b012ece2eb2750ec8818571260f5454c8d52694ebac0870f862705cd_v2"}